Clinical trials sponsored by Replimune, Inc.

Phase breakdown

Conditions studied

Recruiting trials led by Replimune, Inc.

• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 33 locations
• A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
  NCT06887348 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 81 locations

Common questions

How many trials is Replimune, Inc. recruiting for?

Replimune, Inc. is the lead sponsor of 3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.